Studies in aged TASTPM transgenic mice (a model of AD) showed that the oral administration of (-)-epicatechin reduces Aβ pathology through indirect, noncatalytic BACE-1 inhibition and not through modulation of either α- or γ-secretase activity [96]. Here, BACE1 is linked to Alzheimer disease.